Compare DSC & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSC | PRQR |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | China | Netherlands |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.4M | 262.5M |
| IPO Year | 2023 | 2014 |
| Metric | DSC | PRQR |
|---|---|---|
| Price | $4.92 | $1.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $7.78 |
| AVG Volume (30 Days) | 40.0K | ★ 720.9K |
| Earning Date | 12-18-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.21 | $8.25 |
| Revenue Next Year | $56.22 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.52 | $1.33 |
| 52 Week High | $9.60 | $3.10 |
| Indicator | DSC | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 34.28 | 27.72 |
| Support Level | N/A | $1.37 |
| Resistance Level | $7.00 | $1.99 |
| Average True Range (ATR) | 0.82 | 0.08 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 4.87 | 17.24 |
DSC Holdings Ltd is an AI application infrastructure for China's used car industry. According to CIC, the Company has held over 90% market share in operating systems for China's used car dealers, giving it nationwide dealer connections and massive, granular, proprietary, real-time industry data. Building on this digital foundation, the group further supports used car dealers with essential transaction services across their workflows. Its Services engage and benefit thousands of dealer collaborators, such as inspectors, transporters, and other internet platforms, creating an ecosystem with used car dealers at its center.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.